Clinical evidence suggests that anti-PD-1/PD-L1 inhibitors are most effective in inflamed tumors characterized by high tumor PD-L1 expression, CD8+ T-cell infiltration or mutational burden (17–20). Here, PDCD1 is linked to neoplasm.